Danaher (DHR)
(Delayed Data from NYSE)
$268.81 USD
+0.02 (0.01%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $268.75 -0.06 (-0.02%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$268.81 USD
+0.02 (0.01%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $268.75 -0.06 (-0.02%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Zacks News
Carlisle (CSL) Q4 Earnings Beat Estimates, Revenues Decline Y/Y
by Zacks Equity Research
Carlisle (CSL) fourth-quarter 2023 results benefit from higher revenues across the Carlisle Construction Materials segment.
The Zacks Analyst Blog Highlights Eli Lilly, Danaher, Citigroup, Shopify and Canadian Pacific Kansas
by Zacks Equity Research
Eli Lilly, Danaher, Citigroup, Shopify and Canadian Pacific Kansas are included in this Analyst Blog.
Top Stock Reports for Eli Lilly, Danaher & Citigroup
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Danaher Corporation (DHR) and Citigroup Inc. (C).
Markel's (MKL) Q4 Earnings Beat, Revenues Lag Estimates
by Zacks Equity Research
Markel's (MKL) fourth-quarter results reflect improved earned premiums and increased net investment income.
Danaher (DHR) Q4 Earnings Beat, Biotechnology Sales Dip Y/Y
by Zacks Equity Research
While Danaher (DHR) surpasses Q4 earnings and revenue estimates, its performance is hurt by a decrease in the sale of COVID-related products and weak demand in the Biotechnology segment.
Danaher (DHR) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Danaher (DHR) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Danaher (DHR) delivered earnings and revenue surprises of 10% and 6.93%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Griffon (GFF) to Report Q1 Earnings: Is a Beat in Store?
by Zacks Equity Research
Griffon's (GFF) Q1 results are likely to gain from strength in the HBP segment. However, weakness in the CPP segment, along with higher marketing costs, is expected to have hurt its performance.
Honeywell (HON) Gears Up to Post Q4 Earnings: What to Expect?
by Zacks Equity Research
Honeywell's (HON) fourth-quarter results are likely to have benefited from strength across its businesses. Weakness in the warehouse automation market and high costs and expenses might have been spoilsports.
Why Danaher (DHR) Might Surprise This Earnings Season
by Zacks Equity Research
Danaher (DHR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Danaher (DHR) Gears Up to Post Q4 Earnings: Is a Beat in Store?
by Zacks Equity Research
Danaher's (DHR) Q4 earnings are likely to have been hurt by weakness in the Biotechnology and Diagnostics units owing to lower sales of COVID-related products. Improving supply chains and strong price realization are expected to have been positives.
Seeking Clues to Danaher (DHR) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Danaher (DHR), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
Is Invesco Global Water ETF (PIO) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PIO
Danaher (DHR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Danaher (DHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Danaher (DHR) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Danaher (DHR) reachead $231.97 at the closing of the latest trading day, reflecting a +0.4% change compared to its last close.
Can General Electric (GE) Q4 Earnings Beat on Aerospace Boost?
by Zacks Equity Research
Strength in the Aerospace segment and accretive acquisitions are likely to aid General Electric's (GE) fourth-quarter 2023 results.
3M (MMM) Gears Up to Post Q4 Earnings: Is a Beat in Store?
by Zacks Equity Research
3M's (MMM) fourth-quarter 2023 results are likely to have gained from strength across its automotive OEM and medical solutions businesses. However, weak commercial solutions and transportation safety markets might have hurt its results.
Why Danaher (DHR) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Danaher (DHR) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
Danaher (DHR) reachead $226.75 at the closing of the latest trading day, reflecting a +0.67% change compared to its last close.
Danaher (DHR) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
Danaher (DHR) closed the most recent trading day at $229.64, moving -0.53% from the previous trading session.
Danaher (DHR) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
Danaher (DHR) concluded the recent trading session at $230.87, signifying a -1.7% move from its prior day's close.
Here's Why Danaher (DHR) Fell More Than Broader Market
by Zacks Equity Research
The latest trading day saw Danaher (DHR) settling at $230.81, representing a -1.7% change from its previous close.
Should You Invest in the Invesco Global Water ETF (PIO)?
by Zacks Equity Research
Sector ETF report for PIO
Danaher (DHR) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
Danaher (DHR) concluded the recent trading session at $234.79, signifying a +1.49% move from its prior day's close.
Danaher (DHR) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
Danaher (DHR) closed the most recent trading day at $232.86, moving +0.63% from the previous trading session.